Morphic Announces Appointment of Peter G. Linde, M.D., as Chief Medical Officer
Morphic Holding, Inc. (MORF)
Last morphic holding, inc. earnings: 11/12 04:24 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
WALTHAM, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Peter G. Linde, M.D., as chief medical officer. Dr. Linde was previously vice president of medical research at Acceleron Pharma, Inc., where he was responsible for the design and execution of clinical trials with positive outcomes in both pulmonary and hematologic diseases. Dr. Linde will oversee the development of Morphic’s small molecule integrin inhibitors as the company advances its oral integrin inhibitors toward clinical trials. “Dr. Linde has an extensive track record of driving clinical advancement across multiple therapeutic areas including inflammatory, pulmonary and hematologic disease. Notably, his experience includes clinical studies in inflammatory bowel disease, the therapeutic target of MORF-057, our lead oral integrin
Show less
Read more
Impact Snapshot
Event Time:
MORF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MORF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MORF alerts
High impacting Morphic Holding, Inc. news events
Weekly update
A roundup of the hottest topics
MORF
News
- Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024 [Yahoo! Finance]Yahoo! Finance
- Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024GlobeNewswire
- MORF NEWS: Johnson Fistel has Commenced an Investigation on Behalf of Morphic Holding Company ShareholdersGlobeNewswire
- ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
MORF
Earnings
- 4/25/24 - Beat
MORF
Analyst Actions
- 3/8/24 - Canaccord Genuity
MORF
Sec Filings
- 4/26/24 - Form 8-K
- 4/26/24 - Form S-3ASR
- 4/26/24 - Form 424B5
- MORF's page on the SEC website